{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-015898","form_type":"8-K","ticker":"EDIT","cik":"0001650664","company_name":"Editas Medicine, Inc.","filed_at":"2022-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.577166+00:00","generated_at":"2026-06-22T14:19:48.229256+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Editas Q3 net loss $55.7M; second patient dosed in sickle cell trial","bullets":["Net loss $55.7M ($0.81/share) vs $39.1M ($0.57) in Q3 2021.","Collaboration revenue fell to $42K from $6.2M a year ago (2021 had BMS opt-in).","Cash and securities $478.5M, down from $527.6M at June 30; expected to fund into 2024.","Second patient dosed in Phase 1/2 RUBY trial (EDIT-301 for sickle cell); initial data by year-end.","Completed editing for first patient in EDITHAL trial (EDIT-301 for TDT); scheduling dosing."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-015898","json":"https://secwatch.observer/filing/0001558370-22-015898.json","markdown":"https://secwatch.observer/filing/0001558370-22-015898.md","text":"https://secwatch.observer/filing/0001558370-22-015898.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650664/000155837022015898/0001558370-22-015898-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650664/000155837022015898/edit-20221102x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T14:19:48.229256+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"15e4f4d4844f5f6baf7035f6a1898aa190e654c6","claim":"Editas Medicine, Inc. reported the three months ended September 30, 2022 results: revenue $42 thousand, net income $55.7 million, EPS $0.81 per share.","evidence_excerpt":"or $0.81 per share, compared to net loss of $39.1 million, or $0.57 per share, for the same period in 2021. ​ ● Collaboration and other research and development revenues were $42 thousand for the three months ended September 30, 2022, compared to $6.2 million for the same period in 2021. The 2021 period included revenue recognized for an opt-in by Bristol Myers","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1650664/000155837022015898/0001558370-22-015898-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended September 30, 2022"},{"label":"Revenue","value":"$42 thousand"},{"label":"Net income","value":"$55.7 million"},{"label":"EPS","value":"$0.81 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}